跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ARAZLO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ARAZLO
Authorized
STANDARD
ARAZLO
bausch health, canada inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
6773ea5a6cce8db1
Company
bausch health, canada inc.
Type
Standard
Approval Details
Approval Id
6773ea5a6cce8db1
Drug Approval Canada Name
ARAZLO
Product Name
ARAZLO
Status
Marketed
Status Date
2021-09-16
Original Market Date
2021-09-16
Din
02517868
Drug Class
Human
Dosage Form
Lotion
Route Of Administration
Topical
Schedule
Prescription
Ahfs
84:92.00
Atc Original
D05AX05 TAZAROTENE
Atc Name
d 05 ax 05
Aig Number
0133047003
Company Name
bausch health, canada inc.
Company Address
2150 Boul. St-Elzear Ouest, Laval, Quebec, Canada, H7L 4A8
Active Ingredients
TAZAROTENE
0.045 % / W/W
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
6773ea5a6cce8db1
Type
Standard
Back to Health Canada Approvals